We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has requested more safety information before it will allow Pozen and GlaxoSmithKline to market their migraine drug Trexima, the companies said.